GlassScriptPhysician profile
Hima Atluri
NPI 1609866052
$20,985.55
in general payments reported to CMS, 2019-2025
66 companies · $3,322 in 2025
The $3,322 reported for 2025 was more than what 96% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
See the full distribution for Geriatric Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,440 · 2020: $2,421 · 2021: $3,347 · 2022: $3,060 · 2023: $3,046 · 2024: $3,350 · 2025: $3,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,717.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,154.30 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $1,737.62 | 2019-2025 | |
| Amgen INC. | $1,539.78 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $1,500.26 | 2019-2025 | Vraylar, Viberzi, Linzess |
| Novo Nordisk INC | $1,284.80 | 2019-2025 | Wegovy, Ozempic |
| Lilly USA, LLC | $1,279.81 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $1,212.05 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $1,072.57 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,044.74 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $718.99 | 2019-2022 | |
| Abbott Laboratories | $641.80 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Kowa Pharmaceuticals America, INC. | $524.92 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Astellas Pharma US INC | $515.05 | 2019-2025 | Veozah, Myrbetriq |
| Mylan Specialty L.P. | $434.44 | 2019-2024 | Yupelri |
| Neurocrine Biosciences, INC. | $407.00 | 2022-2025 | Ingrezza, Ongentys |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hima Atluri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.